Compare TMC & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMC | NVAX |
|---|---|---|
| Founded | 2011 | 1987 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2020 | 1996 |
| Metric | TMC | NVAX |
|---|---|---|
| Price | $2.28 | $8.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $10.90 | ★ $14.11 |
| AVG Volume (30 Days) | 4.5M | ★ 6.1M |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 232.00 | ★ 309.76 |
| EPS | ★ 0.25 | N/A |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.28 | ★ N/A |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $1.91 | $6.20 |
| 52 Week High | $10.05 | $13.39 |
| Indicator | TMC | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 38.23 | 37.52 |
| Support Level | $1.91 | $7.81 |
| Resistance Level | $2.97 | $10.53 |
| Average True Range (ATR) | 0.25 | 0.76 |
| MACD | 0.04 | -0.16 |
| Stochastic Oscillator | 33.97 | 5.98 |
TMC The Metals Co Inc is a deep seabed minerals developer focused on the collection, processing and refining of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone (CCZ), approximately 1,500 miles (or 2,400 kilometers) south-west of San Diego, California. The company operates as a single operating and reportable segment, namely exploration of seafloor polymetallic nodules, which includes the development of a metallurgical process to treat such seafloor polymetallic nodules.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.